טוען...
Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report
RATIONALE: Lung cancer is the leading cause of cancer-associated deaths all over the world. Although the prognosis of lung cancer has improved over the past decade due to progression in surgical techniques and systematic treatments, the patients with advanced disease still suffer poor survival. Ther...
שמור ב:
| הוצא לאור ב: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wolters Kluwer Health
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6380768/ https://ncbi.nlm.nih.gov/pubmed/30702616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000014328 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|